Tsuruha Holdings stock
3391.TJPXTsuruha Holdings Inc., HealthcareISIN JP3536150000
62Score 62 out of 100, Neutral
Price and trend
69 / 100
Price history
−9.0% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 9.6% above it.
Since April 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 68).
The price is 15% below its 52-week high. Largest decline in 20 years: 62% (May 2018 to April 2022).
Chart figures for advanced users
- SMA 50$14.04
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$14.29
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)68
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$11.92
- The lowest closing price of the last twelve months.
- Resistance$18.51
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Tsuruha Holdings Inc. belongs to the Medical (Pharmaceuticals) industry (Japan) and, with a market value of $7.11B, is number 9 of 15 companies in its industry on MEQIRI.
- In fiscal 2024 it reported revenue of $6.71B (up 4.3% year on year) and earnings of $136.56M (up 0.3%).
- MEQIRI Score 62 out of 100 (Neutral): rank 235 of 702 in Healthcare, median 53.
Show more
- The P/E is 21.6 (Medical (Pharmaceuticals) median 21.2, own median of recent years 22.7).
- Our model puts fair value at $10.75, with the price 45% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Consistently profitableProfit in all 10 fiscal years from 2015 to 2024.Fundamentals 74
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are stability and fundamentals, while profitability and capital allocation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Modestly overvaluedClosing price of 12 Nov 2026, used by the daily score.
In our model the price counts as cheap below $7.68 and expensive above $17.92 (uncertainty high, one part of the fair value is more than twice the other).
The two parts of the fair value come to $6.13 (cash-flow model) and $15.38 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 7%. At 8% the fair value would be $10.31, at 6% it would be $11.38.
Valuation metrics
Half from the dividend model, half from earnings times the industry P/E (21.2).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 31 Aug 2026, revenue rose 91.8% on the twelve months before. Revenue has grown solidly since 2006, at about 11% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2024: gross 30%, operating 4%, net 2%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 22 Dec 2026in 39 days
- Last reported
- 7 Oct 2026EPS reported $0.23 (expected $0.23)in line with expectations
Analyst estimates
Earnings estimates have barely changed since 24 Oct 2026.
- Earnings per share
- $0.67+0.8%
- Revenue
- $15.89B−0.2%
- Earnings per share
- $0.80+0.1%
- Revenue
- $16.38B−0.2%
MEQIRI has stored the estimates since 24 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Tsuruha Holdings
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 62
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Pharmaceuticals)
The next larger and next smaller companies by market value
- Recordati Industria Chimica e FarmaceuticaREC.MI $11.92B74
- Kyowa Kirin4151.T $8.4B77
- Corcept TherapeuticsCORT $8.07B75
- Kiniksa Pharmaceuticals InternationalKNSA $7.56B68
- MatsukiyoCocokara3088.T $6.71B75
- Abbott IndiaABBOTINDIA.NS $6.01B75
- LiquidiaLQDA $5.24B43
- Prestige Consumer HealthcarePBH $2.15B56
ETFs that hold Tsuruha Holdings
Held by 23 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares MSCI Japan Small Cap UCITS ETFIUS4 | 0.24% | 0.58% | €548.59M |
| Amundi Prime Japan UCITS ETF DR (D)PR1J | 0.06% | 0.05% | €4.34B |
| L&G Japan Equity UCITS ETFETLR | 0.05% | 0.10% | €948.97M |
Show 5 more
| Amundi Japan TOPIX II UCITS ETF EUR DistLYY4 | 0.05% | 0.45% | €633.4M |
| iShares Core MSCI Japan IMI UCITS ETFEUNN | 0.05% | 0.12% | €7.17B |
| Vanguard FTSE Japan UCITS ETF EUR Hedged AccumulatingVJPE | 0.04% | 0.13% | €4.58B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.03% | 0.35% | €8.27B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.10% | €395.74M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 13 Nov 2026
- Latest annual report
- Fiscal year 2024, period end 31 May 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ¥159.70)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 3 Oct 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.